AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31097163 — intervention group
Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 243
Study 31097163 — intervention group
Group type: EXPERIMENTAL
Intervention: MVS + PVI
Number of subjects: 243
Study 31097163 — intervention group
Group type: EXPERIMENTAL
Intervention: MVS + biatrial maze
Number of subjects: 243
Study 31097163 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM implantation
Number of subjects: 243
Study 29530020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (herring/mackerel)
Number of subjects: 232
Study 29530020 — intervention group
Group type: COMPARATOR
Intervention: Meat (chicken/lamb/beef)
Number of subjects: 232
Study 27473050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal-volume ventilation (6 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Number of subjects: 25
Study 27473050 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal-volume ventilation (12 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Number of subjects: 25
Study 24680265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration and intracoronary tirofiban combined with nitroprusside bolus (200 µg prior to the first balloon inflation, Group C)
Number of subjects: 90
Study 24680265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration and intracoronary tirofiban bolus (25 µg/kg prior to the first balloon inflation, Group B)
Number of subjects: 90
Study 24680265 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration alone (Group A)
Number of subjects: 90
Study 23124502 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) involvement in educational intervention
Number of subjects: 0
Study 19144653 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 19144653 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 19144653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Angiotensin-converting enzyme inhibitors + Angiotensin receptor blockers)
Number of subjects: 0
Study 17256447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (antidepressants and/or benzodiazepines)
Number of subjects: 1756
Study 17256447 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 1756
Study 17256447 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling or advice from GP
Number of subjects: 1756
Study 15992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnets
Number of subjects: 21
Study 15992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnets (in better quality studies)
Number of subjects: 21
Study 15992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnets (after excluding inadequate treatment studies)
Number of subjects: 21
Study 12162471 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908G tablet
Number of subjects: 40
Study 12162471 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908G suspension
Number of subjects: 40
Study 12162471 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908G tablets
Number of subjects: 40
Study 12162471 — intervention group
Group type: COMPARATOR
Intervention: amprenavir capsules
Number of subjects: 40
Study 9475647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphagen HP with 15.75 g x d(‐1) of HPCE pure creatine monohydrate (HP)
Number of subjects: 25
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel
Number of subjects: 68
Study 8751030 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68
Study 8751030 — intervention group
Group type: COMPARATOR
Intervention: Untreated spots
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Untreated spots
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Placebo gel
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs No treatment (pooled data)
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Placebo gel (pooled data)
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of itching after treatments
Number of subjects: 68
Study 8751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of itching correlation with erythema
Number of subjects: 68
Study 2210982 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine enema alone (Group A, n = 18)
Number of subjects: 81
Study 2210982 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral piperacillin alone (Group B, n = 22)
Number of subjects: 81
Study 2210982 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin in combination with povidone-iodine enema (Group C, n = 25)
Number of subjects: 81
Study 2210982 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D, n = 16)
Number of subjects: 81
Study 345198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin (ASA)
Number of subjects: 32
Study 345198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 345198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 32
Study 345198 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pain sensitivity
Number of subjects: 32
Study 31116274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural drain in the left lateral intercostal region
Number of subjects: 48
Study 31116274 — intervention group
Group type: COMPARATOR
Intervention: Pleural drain in the subxiphoid position
Number of subjects: 48
Study 27809707 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (four-month duration, including two face-to-face sessions and two follow-up calls)
Number of subjects: 100
Study 27809707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 100
Study 25730053 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U/mL BTX‐A injection
Number of subjects: 20
Study 25730053 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 U/mL BTX‐A injection
Number of subjects: 20
Study 25730053 — intervention group
Group type: COMPARATOR
Intervention: Both groups (50 U/mL and 25 U/mL BTX‐A)
Number of subjects: 20
Study 25730053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration group (50 U/mL)
Number of subjects: 20
Study 25730053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration group (25 U/mL)
Number of subjects: 20
Study 24095604 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention regarding anxiety and satisfaction (oral and written information on safety, risks, and benefits of haemotherapy)
Number of subjects: 144
Study 24095604 — intervention group
Group type: COMPARATOR
Intervention: Control group (equivalent information on general health topics)
Number of subjects: 144
Study 24095604 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 144
Study 24095604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 21683209 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic surgery
Number of subjects: 40
Study 21683209 — intervention group
Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 40
Study 21683209 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoperative initial management)
Number of subjects: 40
Study 19699838 — intervention group
Group type: EXPERIMENTAL
Intervention: 113 g serving of 90% lean beef (30 g protein)
Number of subjects: 34
Study 19699838 — intervention group
Group type: EXPERIMENTAL
Intervention: 340 g serving of 90% lean beef (90 g protein)
Number of subjects: 34
Study 17723973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure to P6 point
Number of subjects: 160
Study 17723973 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure to SI3 point
Number of subjects: 160
Study 17723973 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 160
Study 15066073 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble-board training for 5 weeks
Number of subjects: 20
Study 15066073 — intervention group
Group type: COMPARATOR
Intervention: Normal activity only (Control)
Number of subjects: 20
Study 15066073 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble-board training and normal activity (both conditions tested)
Number of subjects: 20
Study 11211888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Hep‐B
Number of subjects: 36
Study 11211888 — intervention group
Group type: COMPARATOR
Intervention: Engerix‐B
Number of subjects: 36
Study 9510452 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 164
Study 9510452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐erythrocyte free iron concentration
Number of subjects: 164
Study 9510452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxanthine levels
Number of subjects: 164
Study 8063021 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir twice daily (first year)
Number of subjects: 1100
Study 8063021 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label acyclovir suppressive therapy (after first year)
Number of subjects: 1100
Study 8063021 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive therapy for 5 years
Number of subjects: 1100
Study 8063021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 1100
Study 2660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 266
Study 2660991 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with dipyridamole
Number of subjects: 266
Study 2660991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 31286397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg kg-1 followed by 0.5 μg kg-1 h-1)
Number of subjects: 60
Study 31286397 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (bolus 0.08 mg kg-1 followed by a saline infusion)
Number of subjects: 60
Study 31286397 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intraoperative morphine consumption
Number of subjects: 60
Study 28012050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 501
Study 28012050 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 501
Study 28012050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after subtraction of theoretical device volume
Number of subjects: 501
Study 28012050 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after subtraction of theoretical device volume
Number of subjects: 501
Study 28012050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after correction for radiofrequency backscattering
Number of subjects: 501
Study 28012050 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after correction for radiofrequency backscattering
Number of subjects: 501
Study 28012050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after correction for echogenicity
Number of subjects: 501
Study 28012050 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after correction for echogenicity
Number of subjects: 501
Study 25972074 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction
Number of subjects: 65
Study 25972074 — intervention group
Group type: COMPARATOR
Intervention: Standard distraction methods
Number of subjects: 65
Study 22517036 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parenteral amino acid intakes (4 g kg(‐1) per day)
Number of subjects: 115
Study 22517036 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral amino acid intakes (3 g kg(‐1) per day)
Number of subjects: 115
Study 22141230 — intervention group
Group type: EXPERIMENTAL
Intervention: High precious alloy + low fusing porcelain (group A)
Number of subjects: 49
Study 22141230 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns (group B)
Number of subjects: 49
Study 19543958 — intervention group
Group type: EXPERIMENTAL
Intervention: CD25(+) regulatory T cells from SIT patients
Number of subjects: 0
Study 19543958 — intervention group
Group type: COMPARATOR
Intervention: CD25(+) regulatory T cells from controls
Number of subjects: 0
Study 19543958 — intervention group
Group type: EXPERIMENTAL
Intervention: CD25(+) regulatory T cells from SIT patients and controls (when cultured together)
Number of subjects: 0
Study 19543958 — intervention group
Group type: EXPERIMENTAL
Intervention: CD25(neg) and CD25(pos) T cells from SIT patients and controls (when cultured together)
Number of subjects: 0
Study 19543958 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT patients
Number of subjects: 0
Study 17221216 — intervention group
Group type: EXPERIMENTAL
Intervention: Goeckerman's therapy (GT)
Number of subjects: 44
Study 17221216 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors (control)
Number of subjects: 44
Study 12582020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aliretinoin (50 mg)
Number of subjects: 114
Study 12582020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aliretinoin (25 mg)
Number of subjects: 114
Study 12582020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 10918204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Number of subjects: 0
Study 9171752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus tPA (three doses of 5 mg over 30 min, then 3.5 mg/h for up to 4 h, then 0.5-1.0 mg/h)
Number of subjects: 100
Study 9171752 — intervention group
Group type: COMPARATOR
Intervention: Low-dose tPA (0.5-1.0 mg/h)
Number of subjects: 100
Study 9114905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg benazepril
Number of subjects: 18
Study 9114905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril
Number of subjects: 18
Study 9114905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3511937 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg acute treatment)
Number of subjects: 0
Study 3511937 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg twice daily for 7 days chronic treatment)
Number of subjects: 0
Study 3511937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3511937 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (acute and chronic treatments)
Number of subjects: 0
Study 29705457 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques (Benson muscle relaxation)
Number of subjects: 105
Study 29705457 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 5% lavender essential oil (2 drops)
Number of subjects: 105
Study 29705457 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular healthcare actions)
Number of subjects: 105
Study 27206122 — intervention group
Group type: EXPERIMENTAL
Intervention: Job strain (high strain jobs)
Number of subjects: 0
Study 27206122 — intervention group
Group type: COMPARATOR
Intervention: Low strain jobs
Number of subjects: 0
Study 27206122 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin angiotensin system antagonists (RASA)
Number of subjects: 0
Study 27206122 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 27206122 — intervention group
Group type: EXPERIMENTAL
Intervention: All medication classes combined
Number of subjects: 0
Study 24646861 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 (sucroferric oxyhydroxide) 1.0-3.0 g per day
Number of subjects: 707
Study 24646861 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate 4.8-14.4 g per day
Number of subjects: 707
Study 24646861 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 maintenance dose
Number of subjects: 707
Study 24646861 — intervention group
Group type: COMPARATOR
Intervention: Low dose (250 mg per day)
Number of subjects: 707
Study 24646861 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21
Number of subjects: 707
Study 24646861 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 707
Study 22329470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Number of subjects: 314
Study 22329470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Number of subjects: 314
Study 22329470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 20578931 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 54 mg or greater
Number of subjects: 100
Study 20578931 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH)
Number of subjects: 100
Study 20578931 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose of OROS MPH
Number of subjects: 100
Study 20578931 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute dose of OROS MPH
Number of subjects: 100
Study 20578931 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline symptom severity
Number of subjects: 100
Study 18626046 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings for 7 days (660 patients)
Number of subjects: 1761
Study 18626046 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (nadroparin, 3800 anti-Xa IU) for 7 days (657 patients)
Number of subjects: 1761
Study 18626046 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (nadroparin, 3800 anti-Xa IU) for 14 days (444 patients)
Number of subjects: 1761
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisal of novelty (factors related to unfamiliarity and complexity)
Number of subjects: 0
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisal of coping potential (the ability to understand the new, complex thing)
Number of subjects: 0
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured and manipulated appraisals
Number of subjects: 0
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports, forced-choice, behavioral measures
Number of subjects: 0
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisal structure specific to interest
Number of subjects: 0
Study 15755222 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisals predicted interest beyond relevant traits (curiosity, openness)
Number of subjects: 0
Study 12698305 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (RGB) 200 mg single oral doses on day 1 and day 7, and Lamotrigine (LTG) 25 mg o.i.d. on days 3-8
Number of subjects: 29
Study 12698305 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG) 200 mg single oral doses on day 1 and day 17, and up-titrated to 300 mg RGB b.i.d. on days 6-20
Number of subjects: 29
Study 10085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who received a sympathetic paper
Number of subjects: 117
Study 10085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who received an unsympathetic paper
Number of subjects: 117
Study 10085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who received a paper incongruent with their beliefs
Number of subjects: 117
Study 10085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who received a paper congruent with their beliefs
Number of subjects: 117
Study 8933494 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training (3 d.wk‐1, 10‐40 min/session, 80‐90% of exercise specific maximal heart rate)
Number of subjects: 42
Study 8933494 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line skating training (3 d.wk‐1, 10‐40 min/session, 80‐90% of exercise specific maximal heart rate)
Number of subjects: 42
Study 8933494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic training)
Number of subjects: 42
Study 1745707 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1, 2, 3, and 4 mg/kg body weight)
Number of subjects: 0
Study 1745707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 6127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 0
Study 6127040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31307925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in NAFLD patients
Number of subjects: 302306
Study 31307925 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery in non-NAFLD patients
Number of subjects: 302306
Study 30135019 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (by percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 9326
Study 30135019 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 9326
Study 30135019 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 9326
Study 26606271 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g·kg⁻¹·h⁻¹ glucose (GLU)
Number of subjects: 14
Study 26606271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g·kg⁻¹·h⁻¹ glucose + 0.3 g·kg⁻¹·h⁻¹ fructose (GLU + FRU)
Number of subjects: 14
Study 26606271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g·kg⁻¹·h⁻¹ glucose + 0.6 g·kg⁻¹·h⁻¹ sucrose (GLU + SUC)
Number of subjects: 14
Study 25287825 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction (RQ‐PCR) for minimal residual disease (MRD) monitoring
Number of subjects: 110
Study 22296837 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models using predictors: age, ISS, GCS, SBP, RR.
Number of subjects: 10210
Study 22296837 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models applied to Khon Kaen data.
Number of subjects: 10210
Study 20824720 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/erlotinib
Number of subjects: 569
Study 20824720 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/placebo
Number of subjects: 569